Renal Clearance Studies
Regarded by some as the clearance experts, DCR’s two clinical pharmacology centers offer a broad range of experience within the clinical pharmacology space
Ready access to DaVita® owned hemodialysis and peritoneal dialysis centers
- Allows for simplified 24-hour monitoring when conducting dialysis studies
- Provides condensed project feasibility by allowing access to our proprietary database system across multiple disease states
Highly specialized trials with focused subject population requiring specific conditions
- Conducted more than 90 such trials in the last five years
- Enrolled 885 subjects with an average enrollment timeframe of 2-5 months
DCR’s team is headed by Harry Alcorn, Jr., PharmD, Chief Scientific Officer
- Conducted over 300 renal protocols
- Enrolled over 8,000 subjects with mild, moderate, or severe renal function and those on hemodialysis or peritoneal dialysis
- Dr. Alcorn has written over 50 renal protocols and consulted on study design, inclusion/exclusion criteria, and drug-drug interactions in renal patients on over 200 protocols
DCR has the capability to define and understand GFR
- A measure of pre-renal blood flow of a drug
- Helps understand if there is an impact on renal function and whether it is real or artifact
DCR offers a team of highly experienced and qualified staff
- Backed by the DaVita Inc. brand that volunteers and sponsors alike recognize for quality, integrity and safety
An active renal research database for this patient population consists of 567 Pre-ESRD and 2,700 ESRD patients on dialysis